Review anchor
Endothelial PAS domain-containing protein 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Endothelial PAS domain-containing protein 1
CHEMBL1744522
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Endothelial PAS domain-containing protein 1 as ChEMBL target CHEMBL1744522, mapped to UniProt Q99814. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL1744522
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q99814
Endothelial PAS domain-containing protein 1
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Endothelial PAS domain-containing protein 1 matters
Endothelial PAS domain-containing protein 1 is reviewed as Endothelial PAS domain-containing protein 1 (UniProt Q99814); Endothelial PAS domain-containing protein 1 shows approved-linked disease relevance led by clear cell renal carcinoma. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 2 approved drugs, 614 compounds, and 93 assays, with lead potency reaching pChEMBL 8.7.
Protein context
Endothelial PAS domain-containing protein 1
Endothelial PAS domain-containing protein 1 Sequence length is 870 aa.
Review this target as Endothelial PAS domain-containing protein 1, mapped to UniProt Q99814. Sequence length is 870 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q99814
Protein
Disease context
clear cell renal carcinoma
Endothelial PAS domain-containing protein 1 shows approved-linked disease relevance led by clear cell renal carcinoma. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include BELZUTIFAN.
Start review with clear cell renal carcinoma because it currently carries approved-linked support. Linked drugs include BELZUTIFAN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
1 linked drug
Activity base
Portfolio and assay base
ChEMBL currently tracks 2 approved drugs, 614 compounds, and 93 assays for this target. The dominant activity type is IC50. CHEMBL5590666 is the current potency anchor at pChEMBL 8.7.
Use CHEMBL5590666 as the tractability anchor when discussing potency (pChEMBL 8.7).
Activity source · ChEMBL 36 via Core Engine
2 approved
pChEMBL 8.7
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Endothelial PAS domain-containing protein 1 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q99814, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why clear cell renal carcinoma is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
614
Total Compounds
93
Total Assays
2
Approved Drugs
IC50: 545.0, EC50: 171.0, KD: 110.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL5590666
|
8.7 | EC50 | — |
|
|
No preferred name
CHEMBL4453227
|
8.4 | EC50 | — |
|
|
No preferred name
CHEMBL4172666
|
8.3 | IC50 | — |
|
|
No preferred name
CHEMBL4165848
|
8.2 | EC50 | — |
|
|
No preferred name
CHEMBL6004325
|
8.2 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
BELZUTIFAN
CHEMBL4585668
|
2021 |
Source Header